Document Detail


Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler.
MedLine Citation:
PMID:  18158708     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin-converting enzyme (ACE) inhibitors can improve cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM). Myocardial diastolic function (Ve) is a known marker of cardiovascular prognosis. It could potentially indicate the effects of preventive therapy if evaluated by tissue Doppler. We tested the hypothesis that treatment with the ACE inhibitor ramipril has beneficial effects on Ve. In this study, 16 subjects on insulin therapy (eight receiving 10 mg ramipril/day compared to eight matched controls who were not treated with an ACE inhibitor) were followed up for a period of nine months. Myocardial and vascular function were assessed by tissue Doppler and ultrasound. In the ramipril group, Ve improved significantly after nine months of treatment (7.8+/-0.9 cm/s to 8.6+/-0.9 cm/s, p<0.04). Systolic blood pressure and intima media thickness (IMT) demonstrated a trend towards improvement. In controls, Ve remained unchanged and there was a trend towards deterioration in stiffness index beta (p<0.07). In conclusion, the observed improvement of myocardial diastolic function with ramipril in patients with T2DM is an encouraging result. It might contribute to the overall improvement that has been observed with hard cardiovascular end points.
Authors:
Thorsten Siegmund; Petra-Maria Schumm-Draeger; Diethmar Antoni; Helene Von Bibra
Related Documents :
18031738 - Pharmacological profile of the new inotropic agent at-11.
7026198 - Captopril withdrawal after chronic therapy.
1680688 - Therapeutic alternatives in dilated cardiomyopathy--a review of current options.
11150728 - Kinin-degrading pathways in the human heart.
7128668 - Sympathomimetic effects of amezinium on the cardiovascular system and plasma catecholam...
1896168 - The glaucoma laser trial: 4. contralateral effects of timolol on the intraocular pressu...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease     Volume:  4     ISSN:  1479-1641     ISO Abbreviation:  -     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-25     Completed Date:  2008-02-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101234011     Medline TA:  Diab Vasc Dis Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  358-64     Citation Subset:  IM    
Affiliation:
Department of Endocrinology, Diabetes and Vascular Medicine, Academic Teaching Hospital Munich-Bogenhausen, Munich, Germany. thorsten_siegmund@gmx.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Diabetes Mellitus, Type 2 / drug therapy*,  metabolism
Diastole / drug effects*
Echocardiography, Doppler
Female
Hemodynamics / drug effects
Humans
Male
Middle Aged
Pilot Projects
Prospective Studies
Ramipril / therapeutic use*
Systole / drug effects
Ventricular Function / drug effects*,  physiology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The European perspective on diabetes prevention: development and Implementation of A European Guidel...
Next Document:  Microalbuminuria and the metabolic syndrome in non-diabetic black Africans.